Dicerna Pharmaceuticals, Inc.

27 patents currently held · Updated Nov 15, 2026

57 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

Ending by 2030

Jul 2031

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Nov 30, 2026
The maintenance fee for Compositions and methods for inhibiting ALDH2 expression (US 11,661,603) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
1 fee due Dec 6, 2026
The maintenance fee for Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA (US 11,667,918) comes due Dec 6, 2026. Unpaid by Jun 7, 2027, it lapses early.
1 fee due Jan 11, 2027
The maintenance fee for Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA (US 11,697,812) comes due Jan 11, 2027. Unpaid by Jul 12, 2027, it lapses early.
1 fee due Apr 3, 2027
The maintenance fee for Methods and Compositions for the Specific Inhibition of Complement Component 5(C5) by Double-Stranded RNA (US 11,773,390) comes due Apr 3, 2027. Unpaid by Oct 4, 2027, it lapses early.
1 fee due May 14, 2027
The maintenance fee for Reducing Beta-Catenin and Ido Expression to Potentiate Immunotherapy (US 11,813,280) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
1 fee due Jun 8, 2027
The maintenance fee for Methods and Compositions for the Specific Inhibition of HIF-1A by Double-Stranded RNA (US 9,206,420) comes due Jun 8, 2027. Unpaid by Dec 8, 2027, it lapses early.
1 fee due Jul 26, 2027
The maintenance fee for Methods and Compositions for the Specific Inhibition of Beta-Catenin by Double-Stranded RNA (US 9,243,244) comes due Jul 26, 2027. Unpaid by Jan 26, 2028, it lapses early.
1 fee due Oct 7, 2027
The maintenance fee for Methods and Compositions for the Specific Inhibition of Beta-Catenin by Double-Stranded RNA (US 10,612,023) comes due Oct 7, 2027. Unpaid by Apr 7, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

1 of the patents on this record was granted since Aug 17, 2026
3 terms have ended since Aug 17, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 10,612,023	Methods and Compositions for the Specific Inhibition of Beta-Catenin by Double-Stranded RNA In force Term ends Jul 1, 2031 · Medium confidence	In force	Term ends Jul 1, 2031	Medium confidence
US 8,927,515	Methods and Compositions for the Specific Inhibition of Androgen Receptor by Double-Stranded RNA In force Term ends Sep 26, 2031 · Medium confidence	In force	Term ends Sep 26, 2031	Medium confidence
US 9,243,244	Methods and Compositions for the Specific Inhibition of Beta-Catenin by Double-Stranded RNA In force Term ends Oct 3, 2031 · Medium confidence	In force	Term ends Oct 3, 2031	Medium confidence
US 9,206,420	Methods and Compositions for the Specific Inhibition of HIF-1A by Double-Stranded RNA In force Term ends Mar 24, 2032 · Medium confidence	In force	Term ends Mar 24, 2032	Medium confidence
US 9,365,850	Methods and compositions for the specific inhibition of MYC by double-stranded RNA In force Term ends Sep 12, 2033 · From the USPTO record	In force	Term ends Sep 12, 2033	From the USPTO record
US 10,150,965	Methods and Compositions for the Specific Inhibition of Transthyretin (TTR) by Double-Stranded RNA In force Term ends Dec 5, 2034 · High confidence	In force	Term ends Dec 5, 2034	High confidence
US 10,676,742	Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA In force Ends no later than Dec 5, 2034 · From the USPTO record	In force	Ends no later than Dec 5, 2034	From the USPTO record
US 11,697,812	Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA In force Ends no later than Dec 5, 2034 · From the USPTO record	In force	Ends no later than Dec 5, 2034	From the USPTO record
US 10,689,647	Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA In force Term ends May 9, 2036 · From the USPTO record	In force	Term ends May 9, 2036	From the USPTO record
US 11,773,390	Methods and Compositions for the Specific Inhibition of Complement Component 5(C5) by Double-Stranded RNA In force Term ends Dec 7, 2036 · High confidence	In force	Term ends Dec 7, 2036	High confidence

10 of 27 patents shown.

Pro members see all 27.

Pro members: see all 27 patents

Also on record, not counted in the 27: 57 patents in force now held by others · 20 lapsed for an unpaid fee · 6 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

14 pending · 15 abandoned · 22 no status recorded

List them